Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure

Bibliographic Details
Main Authors:	Shingo Kato, Nobuyuki Horita, Daisuke Utsunomiya, Jing Ni
Format:	Article
Language:	English
Published:	Wolters Kluwer 2023-04-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000002652

Similar Items

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
by: Shingo Kato, et al.
Published: (2022-10-01)

Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
by: Jiangjun Wei, et al.
Published: (2023-04-01)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
by: Juexing Li, et al.
Published: (2022-09-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
by: Muhammad Shahzeb Khan, et al.
Published: (2019-11-01)

Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations
by: Kyoung Hwa Ha, et al.
Published: (2024-03-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia
by: Yu Horiuchi, et al.
Published: (2024-03-01)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
by: Donato Cappetta, et al.
Published: (2021-12-01)

Update on the efficacy and safety of sodium–glucose cotransporter 2 inhibitors in Asians and non‐Asians
by: Yoshihito Fujita, et al.
Published: (2019-11-01)

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
by: Thomas A Zelniker, et al.
Published: (2019-01-01)

Sodium‐glucose cotransporter 2 inhibitors are associated with reduced risk of mortality and readmissions in heart failure
by: Patric Karlström, et al.
Published: (2024-02-01)

Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
by: Dominik Kurczyński, et al.
Published: (2022-07-01)

Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure
by: Takahiro Kambara, et al.
Published: (2019-12-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
by: Jaime A Davidson, et al.
Published: (2023-02-01)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
by: Ming-Lung Tsai, et al.
Published: (2023-05-01)

Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
by: Jun Muneuchi, et al.
Published: (2022-01-01)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
by: Julie Kolwelter, et al.
Published: (2021-12-01)

Sodium‐glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
by: Roy Rasalam, et al.
Published: (2021-10-01)

Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
by: Wenqin Guo, et al.
Published: (2024-04-01)

Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
by: Masaki Nakagaito, et al.
Published: (2021-07-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials
by: Luxi Ji, et al.
Published: (2023-03-01)

Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics
by: Yi‐Fang Weng, et al.
Published: (2023-04-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

Research Progress of Sodium-glucose-cotransporter-2 Inhibitors in Patients with Heart Failure with Mildly Reduced Ejection Fraction
by: Dong AN, Shuren LI, Fei LUO, Xiao HAO
Published: (2022-07-01)

Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
by: Juan Tamargo
Published: (2019-01-01)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022-11-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
by: Arjun K. Pandey, et al.
Published: (2022-04-01)

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
by: Luka Cavka, et al.
Published: (2021-08-01)

Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series
by: Matthew Griffin, et al.
Published: (2020-08-01)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022-02-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022-11-01)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
by: Muhammad Afzal, et al.
Published: (2021-11-01)

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
by: Juan Tamargo
Published: (2019-12-01)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion
by: Michelle Hernandez, et al.
Published: (2022-04-01)

Short‐term outcomes after sodium‐glucose cotransporter‐2 inhibitor initiation in a cohort of heart failure patients
by: Bryan O. Pérez Martínez, et al.
Published: (2023-10-01)